Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cardiovascular Diabetology

Topics

Medicine

Internal Medicine

Endocrinology

Surgery

Nephrology

Show all topics

DOI

10.1186/s12933-014-0148-1

License

CC-BY

Other Formats

PDF